Understanding the causes of pulmonary arterial hypertension
Molecular pathogenesis of pulmonary arterial hypertension
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-10772007
This study is looking into how certain gene changes might affect people with pulmonary arterial hypertension (PAH) and aims to find new treatments for those with these genetic mutations.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-10772007 on ClinicalTrials.gov |
What this research studies
This research investigates pulmonary arterial hypertension (PAH), a serious condition that causes high blood pressure in the lungs and can lead to heart failure. The focus is on understanding the genetic factors, particularly mutations in the BMPR2 gene, that contribute to the disease's progression. Researchers will explore how DNA damage affects the cells in the pulmonary arteries and whether this damage is a cause or a result of PAH. By identifying the mechanisms involved, the goal is to develop targeted therapies for patients with BMPR2 mutations.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension, particularly those with mutations in the BMPR2 gene.
Not a fit: Patients with pulmonary arterial hypertension who do not have BMPR2 mutations may not benefit directly from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve outcomes for patients with pulmonary arterial hypertension.
How similar studies have performed: Previous research has shown promising results in understanding the genetic basis of pulmonary arterial hypertension, but this specific approach to linking DNA damage with BMPR2 mutations is relatively novel.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HATA, AKIKO — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: HATA, AKIKO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Disorder